Search
Filter Results
Displaying 91–100 of 749 for “retinal diseases”
-
Nov 17, 2026
Foundation NewsThe commitment directs $700,000 to the Gund Vision Fund, to be matched by the Gordon and Llura Gund Foundation as part of the Fund’s ongoing fundraising campaign, and $300,000 to a Foundation Fighting Blindness research award advancing a regenerative, gene-agnostic therapy
-
Sep 15, 2026
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research for retinitis pigmentosa treatments.
-
Quarterly vision webinars providing key information impacting our community.
-
Apr 28, 2023
Research NewsDr. Tucker is leading the development of GMP facilities for manufacturing clinical grade retinal therapies
-
Jul 5, 2018
Retinal Regeneration: Releasing Your Inner Salamander
Research NewsMany research groups from around the world are investigating ways to create new photoreceptors from stem cells for transplantation into the retina for vision restoration.
-
Oct 18, 2024
MicroRNA Breakthroughs: Paving the Way for Vision Restoration
Research NewsResearchers funded by the Foundation Fighting Blindness are developing microRNA-based therapies for inherited retinal diseases, building on recent Nobel Prize-winning discoveries.
-
Aug 6, 2018
FFB Funding More than $2 Million in New Research
Research NewsSeventy scientists submitted requests for funding.
-
Jun 21, 2023
Dan Day - Making a Difference Now and for Future Generations
Beacon Stories“Because I have seen such tremendous progress over the years, and I want that progress to continue until the day when we have cures for all retinal diseases, it is important to me that the Foundation be part of my lasting legacy.”
-
Apr 22, 2026
In the PressFour-year cohort will enroll participants with inherited retinal diseases caused by mutations in the RHO gene. Study is intended to deepen understanding of disease progression and inform future clinical trial design in rhodopsin-associated retinal disease.
-
Apr 10, 2025
Foundation NewsThe partnership will formalize an ongoing commitment by both companies to accelerate the development of treatments and cures for retinal diseases, while prioritizing a patient-centric approach.